Cellectar Biosciences has secured a multi‑year supply of the two most critical alpha‑emitting radioisotopes—Actinium‑225 and Astatine‑211—from Ionetix Corporation, a move that removes a major bottleneck in the company’s flagship targeted alpha‑therapy program, CLR‑225.
The agreement, announced on December 16 2025, obligates Ionetix to produce the isotopes at commercial scale, leveraging a newly installed second cyclotron at its Michigan facility. While the financial terms and exact volumes remain undisclosed, the partnership is designed to provide a reliable, cGMP‑grade supply that can meet the escalating demands of future clinical programs.
Cellectar’s supply chain has previously included agreements with NorthStar Medical Radioisotopes (starting in 2025) and ITM Isotope Technologies Munich (announced September 2025). The Ionetix deal complements these arrangements, ensuring that the company has multiple, geographically diversified sources and reducing the risk of supply interruptions that could delay the initiation of human trials.
From a business perspective, the new agreement enables Cellectar to advance CLR‑225 into clinical testing without the uncertainty that has historically plagued alpha‑therapy development. COO Jarrod Longcor emphasized that a dependable isotope supply is “critical to maintaining the momentum of our pipeline and avoiding costly delays.” The partnership also positions Cellectar to potentially lower future capital expenditures associated with isotope procurement.
The targeted alpha‑therapy market is expanding rapidly, driven by the need for more effective treatments for solid tumors. However, the scarcity of Ac‑225 and At‑211 has been a persistent headwind. Ionetix’s investment in a second cyclotron and its track record in isotope production give the company a competitive edge, and the new supply agreement signals to investors that Cellectar is proactively addressing a key operational risk.
Overall, the multi‑year agreement strengthens Cellectar’s strategic footing, accelerates the development timeline for CLR‑225, and enhances the company’s resilience in a market where supply constraints can derail even the most promising therapies. The deal is a clear indicator that Cellectar is positioning itself to capitalize on the growing demand for targeted alpha‑therapy solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.